Caerulomycin A—An Antifungal Compound Isolated from Marine Actinomycetes

Actinomycetes have been prolific sources of novel secondary metabolites with a range of biological activities that may ultimately find application as therapeutic compounds. Hence several drug discovery companies are engaged in isolation of novel bioactive metabolites from these microbial sources. Antibiotics form the major class of such bioactive metabolites and have been widely used for treating infectious diseases. One of the most critical problems in clinical practice is the increase of prevalence of drug resistant strains, especially azole resistance among fungi. Due to this, there is a constant need for development of new antifungal antibiotics having novel scaffolds and/or mechanism of action. In our in-house screening program in the quest of novel and superior antifungal compounds, an actinomycetes strain PM0525875 was isolated from a marine invertebrate. The extracts of this microbe showed potent in-vitro antifungal activity against drug resistant fungal strains. The antifungal active peak from the extract obtained by shake flask fermentation was identified by chromatographic and other analytical techniques during bioactivity guided isolation. Later the fermentation conditions were optimized in 30 L fermentor for the production of sufficient amount antifungal compound for complete structural characterization. Consequently the fermented broth extract was subjected to bioactivity-guided fractionation, to isolate the active principle using different preparative chromatographic techniques followed by its characterization. The active principle was characterized to be Caerulomycin A. Minimum inhibitory concentration (MIC) of the compound was found in the range of 0.39 - 1.56 μg/ml against pathogenic fungal test strains. The phylogenetic analysis of producer strain using 16S rRNA sequence showed closest match with Actinoalloateichus cyanogriseus. Herewith we report the isolation of Caerulomycin A from marine invertebrate-associated Actinoalloteichus sp. using optimized medium and fermentation conditions.

[1]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[2]  R. Shi,et al.  Insights into caerulomycin A biosynthesis: a two-component monooxygenase CrmH-catalyzed oxime formation. , 2013, Journal of the American Chemical Society.

[3]  M. Kollef,et al.  Secular Trends in Candidemia-Related Hospitalization in the United States, 2000–2005 , 2008, Infection Control & Hospital Epidemiology.

[4]  R. S. Forrest,et al.  Determination of Yeast Carbohydrates with the Anthrone Reagent , 1952, Nature.

[5]  J. Felsenstein CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP , 1985, Evolution; international journal of organic evolution.

[6]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[7]  D. K. Chatterjee,et al.  Caerulomycin, an antifungal antibiotic with marked in vitro and in vivo activity againstEntamoeba histolytica , 2004, Zeitschrift für Parasitenkunde.

[8]  J. Venkatesan,et al.  RETRACTED: Marine actinobacterial metabolites: current status and future perspectives. , 2013, Microbiological research.

[9]  Jesús Martín,et al.  Current approaches to exploit actinomycetes as a source of novel natural products , 2011, Journal of Industrial Microbiology & Biotechnology.

[10]  K. S. Lam,et al.  Discovery of novel metabolites from marine actinomycetes. , 2006, Current opinion in microbiology.

[11]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[12]  L. Vining,et al.  Caerulomycins B and C, new 2,2′-dipyridyl derivatives from Streptomyces caeruleus , 1977 .

[13]  D. Faulkner,et al.  Marine natural products. , 2000, Natural product reports.

[14]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  O. Genilloud,et al.  Actinomycetes isolated from lichens: evaluation of their diversity and detection of biosynthetic gene sequences. , 2005, FEMS microbiology ecology.

[16]  B. Bonev,et al.  Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. , 2008, The Journal of antimicrobial chemotherapy.

[17]  S. Zotchev Marine actinomycetes as an emerging resource for the drug development pipelines. , 2012, Journal of biotechnology.

[18]  O. Mongin,et al.  First synthesis of caerulomycin B. A new synthesis of caerulomycin C. , 2002, The Journal of organic chemistry.

[19]  M. Kimura A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences , 1980, Journal of Molecular Evolution.

[20]  A. Bull,et al.  Erratum , 2005, Antonie van Leeuwenhoek.

[21]  A. Mortimer,et al.  The production of polyenic antibiotics by soil streptomycetes. , 1957, Journal of general microbiology.

[22]  O. Genilloud,et al.  Terrestrial Microorganisms – Filamentous Bacteria , 2010 .

[23]  P. Northcote,et al.  Marine natural products. , 2006, Natural product reports.

[24]  P. Parameswaran,et al.  Recent advances in marine drug research. , 2013, Biotechnology advances.

[25]  L. Vining,et al.  Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. II. Structure , 1967 .

[26]  A. Funk,et al.  Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. I. Production, isolation, assay, and biological properties. , 1959, Canadian journal of microbiology.

[27]  J. Bérdy Bioactive Microbial Metabolites A Personal View , 2005 .

[28]  Ó. Salazar,et al.  Real-Time PCR for the Detection and Quantification of Geodermatophilaceae from Stone Samples and Identification of New Members of the Genus Blastococcus , 2006, Applied and Environmental Microbiology.

[29]  János Bérdy,et al.  Bioactive microbial metabolites. , 2005, The Journal of antibiotics.

[30]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.